Global Antisense and RNAi Therapeutics Market Overview:
Global Antisense and RNAi Therapeutics Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Antisense and RNAi Therapeutics Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Antisense and RNAi Therapeutics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Antisense and RNAi Therapeutics Market:
The Antisense and RNAi Therapeutics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Antisense and RNAi Therapeutics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Antisense and RNAi Therapeutics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Antisense and RNAi Therapeutics market has been segmented into:
Antisense RNA
RNA Interference
By Application, Antisense and RNAi Therapeutics market has been segmented into:
Pulmonary Delivery
Intravenous Injections
Intra-Dermal Injections
Intraperitoneal Injections
Topical Delivery
Other Route of Administrations).
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Antisense and RNAi Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Antisense and RNAi Therapeutics market.
Top Key Players Covered in Antisense and RNAi Therapeutics market are:
Acuitas Therapeutics
Alnylam Pharmaceuticals
Antisense Therapeutics Ltd.
Arbutus Biopharma
Benitec Biopharma Ltd.
Bio-Path Holdings Inc.
Calando Pharmaceuticals
Dicerna Pharmaceuticals
Enzon Pharmaceuticals Inc
Gene Signal
GlaxoSmithKline Plc
Gradalis
iCo Therapeutics
Ionis Pharmaceuticals
Lorus Therapeutics (Aptose Biosciences)
Marina Biotech
miRagen Therapeutics
Mirna Therapeutics Inc
Olix Pharmaceuticals
OncoGeneX Pharmaceuticals
Quark Pharmaceuticals
Regulus Therapeutics
Rexahn Pharmaceuticals
Rxi Pharmaceuticals
Sanofi S.A
Santaris Pharma A/S (Roche)
Sarepta Therapeutics
Silence Therapeutics Plc
Sirnaomics Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Antisense and RNAi Therapeutics Market Type
4.1 Antisense and RNAi Therapeutics Market Snapshot and Growth Engine
4.2 Antisense and RNAi Therapeutics Market Overview
4.3 Antisense RNA
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Antisense RNA: Geographic Segmentation Analysis
4.4 RNA Interference
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 RNA Interference: Geographic Segmentation Analysis
Chapter 5: Antisense and RNAi Therapeutics Market Application
5.1 Antisense and RNAi Therapeutics Market Snapshot and Growth Engine
5.2 Antisense and RNAi Therapeutics Market Overview
5.3 Pulmonary Delivery
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Pulmonary Delivery: Geographic Segmentation Analysis
5.4 Intravenous Injections
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Intravenous Injections: Geographic Segmentation Analysis
5.5 Intra-Dermal Injections
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Intra-Dermal Injections: Geographic Segmentation Analysis
5.6 Intraperitoneal Injections
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Intraperitoneal Injections: Geographic Segmentation Analysis
5.7 Topical Delivery
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Topical Delivery: Geographic Segmentation Analysis
5.8 Other Route of Administrations).
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Other Route of Administrations).: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Antisense and RNAi Therapeutics Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ACUITAS THERAPEUTICS; ALNYLAM PHARMACEUTICALS; ANTISENSE THERAPEUTICS LTD.; ARBUTUS BIOPHARMA; BENITEC BIOPHARMA LTD.; BIO-PATH HOLDINGS INC.; CALANDO PHARMACEUTICALS; DICERNA PHARMACEUTICALS; ENZON PHARMACEUTICALS INC; GENE SIGNAL; GLAXOSMITHKLINE PLC; GRADALIS; ICO THERAPEUTICS; IONIS PHARMACEUTICALS; LORUS THERAPEUTICS (APTOSE BIOSCIENCES); MARINA BIOTECH; MIRAGEN THERAPEUTICS; MIRNA THERAPEUTICS INC; OLIX PHARMACEUTICALS; ONCOGENEX PHARMACEUTICALS; QUARK PHARMACEUTICALS; REGULUS THERAPEUTICS; REXAHN PHARMACEUTICALS; RXI PHARMACEUTICALS; SANOFI S.A; SANTARIS PHARMA A/S (ROCHE); SAREPTA THERAPEUTICS; SILENCE THERAPEUTICS PLC; SIRNAOMICS INC.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
Chapter 7: Global Antisense and RNAi Therapeutics Market By Region
7.1 Overview
7.2. North America Antisense and RNAi Therapeutics Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Antisense RNA
7.2.2.2 RNA Interference
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Pulmonary Delivery
7.2.3.2 Intravenous Injections
7.2.3.3 Intra-Dermal Injections
7.2.3.4 Intraperitoneal Injections
7.2.3.5 Topical Delivery
7.2.3.6 Other Route of Administrations).
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Antisense and RNAi Therapeutics Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Antisense RNA
7.3.2.2 RNA Interference
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Pulmonary Delivery
7.3.3.2 Intravenous Injections
7.3.3.3 Intra-Dermal Injections
7.3.3.4 Intraperitoneal Injections
7.3.3.5 Topical Delivery
7.3.3.6 Other Route of Administrations).
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Antisense and RNAi Therapeutics Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Antisense RNA
7.4.2.2 RNA Interference
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Pulmonary Delivery
7.4.3.2 Intravenous Injections
7.4.3.3 Intra-Dermal Injections
7.4.3.4 Intraperitoneal Injections
7.4.3.5 Topical Delivery
7.4.3.6 Other Route of Administrations).
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Antisense and RNAi Therapeutics Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Antisense RNA
7.5.2.2 RNA Interference
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Pulmonary Delivery
7.5.3.2 Intravenous Injections
7.5.3.3 Intra-Dermal Injections
7.5.3.4 Intraperitoneal Injections
7.5.3.5 Topical Delivery
7.5.3.6 Other Route of Administrations).
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Antisense and RNAi Therapeutics Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Antisense RNA
7.6.2.2 RNA Interference
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Pulmonary Delivery
7.6.3.2 Intravenous Injections
7.6.3.3 Intra-Dermal Injections
7.6.3.4 Intraperitoneal Injections
7.6.3.5 Topical Delivery
7.6.3.6 Other Route of Administrations).
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Antisense and RNAi Therapeutics Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Antisense RNA
7.7.2.2 RNA Interference
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Pulmonary Delivery
7.7.3.2 Intravenous Injections
7.7.3.3 Intra-Dermal Injections
7.7.3.4 Intraperitoneal Injections
7.7.3.5 Topical Delivery
7.7.3.6 Other Route of Administrations).
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Antisense and RNAi Therapeutics Scope:
|
Report Data
|
Antisense and RNAi Therapeutics Market
|
|
Antisense and RNAi Therapeutics Market Size in 2025
|
USD XX million
|
|
Antisense and RNAi Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Antisense and RNAi Therapeutics Base Year
|
2024
|
|
Antisense and RNAi Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Acuitas Therapeutics, Alnylam Pharmaceuticals, Antisense Therapeutics Ltd., Arbutus Biopharma, Benitec Biopharma Ltd., Bio-Path Holdings Inc., Calando Pharmaceuticals, Dicerna Pharmaceuticals, Enzon Pharmaceuticals Inc, Gene Signal, GlaxoSmithKline Plc, Gradalis, iCo Therapeutics, Ionis Pharmaceuticals, Lorus Therapeutics (Aptose Biosciences), Marina Biotech, miRagen Therapeutics, Mirna Therapeutics Inc, Olix Pharmaceuticals, OncoGeneX Pharmaceuticals, Quark Pharmaceuticals, Regulus Therapeutics, Rexahn Pharmaceuticals, Rxi Pharmaceuticals, Sanofi S.A, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Silence Therapeutics Plc, Sirnaomics Inc..
|
|
Key Segments
|
By Type
Antisense RNA
RNA Interference
By Applications
Pulmonary Delivery
Intravenous Injections
Intra-Dermal Injections
Intraperitoneal Injections
Topical Delivery
Other Route of Administrations).
|
